Sexuality in premature ovarian insufficiency

References

• Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond Engl) 2015;11:169–82
   PubMedGoogle Scholar
• Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604–6
   PubMed Web of Science ®Google Scholar
• Luborsky JL, Meyer P, Sowers MF, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003;18:199–206
   PubMed Web of Science ®Google Scholar
• Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009;360:606–14
   PubMed Web of Science ®Google Scholar
• Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Womens Health 2014;6:235–43
   PubMedGoogle Scholar
• Santoro N. Mechanisms of premature ovarian failure. Ann Endocrinol (Paris) 2003;64:87–92
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril 2016;106:1580–7
   PubMed Web of Science ®Google Scholar
• De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010;376:911–21
   PubMed Web of Science ®Google Scholar
• Allshouse AA, Semple AL, Santoro NF. Evidence for prolonged and unique amenorrhea-related symptoms in women with premature ovarian failure/primary ovarian insufficiency. Menopause 2015;22:166–74
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015;18:483–91
   PubMed Web of Science ®Google Scholar
• Ben-Nagi J, Panay N. Premature ovarian insufficiency: how to improve reproductive outcome? Climacteric 2014;17:242–6
   PubMed Web of Science ®Google Scholar
• Panay N, Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol 2009;23:129–40
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril 2016;106:1588–99
   PubMed Web of Science ®Google Scholar
• Muka T, Oliver-Williams C, Kunutsor S. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016;1:767–76
   PubMed Web of Science ®Google Scholar
• Graziottin A. Menopause and sexuality: key issues in premature menopause and beyond. Ann N Y Acad Sci 2010;1205:254–61
   PubMed Web of Science ®Google Scholar
• Simon JA, Davis SR, Althof SE. Sexual well-being after menopause: an International Menopause Society White Paper. Climacteric 2018;21:415–27
   PubMed Web of Science ®Google Scholar
• Mann E, Singer D, Pitkin J, et al. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric 2012;15:481–9
   PubMed Web of Science ®Google Scholar
• Singer D, Mann E, Hunter MS, et al. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric 2011;14:428–37
   PubMed Web of Science ®Google Scholar
• Kalantaridou SN, Vanderhoof VH, Calis KA, et al. Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. Fertil Steril 2008;90:1805–11
   PubMed Web of Science ®Google Scholar
• van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15:23–31
   PubMed Web of Science ®Google Scholar
• De Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011;18:262–6
   PubMed Web of Science ®Google Scholar
• Benetti-Pinto CL, Soares PM, Giraldo HP, et al. Role of the different sexuality domains on the sexual function of women with premature ovarian failure. J Sex Med 2015;12:685–9
   PubMed Web of Science ®Google Scholar
• Pacello PC, Yela DA, Rabelo S, et al. Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric 2014;17:342–7
   PubMed Web of Science ®Google Scholar
• Althof SE, Meston CM, Perelman MA, et al. Opinion paper: on the diagnosis/classification of sexual arousal concerns in women. J Sex Med 2017;14:1365–71
   PubMed Web of Science ®Google Scholar
• Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. Menopause 2004;11:766–77
   PubMed Web of Science ®Google Scholar
• Nappi RE, Polatti F. The use of estrogen therapy in women’s sexual functioning (CME). J Sex Med 2009;6:603–16
   PubMed Web of Science ®Google Scholar
• Nappi RE, Domoney C. Pharmacogenomics and sexuality: a vision. Climacteric 2013;16:25–30
   PubMed Web of Science ®Google Scholar
• Nappi RE, Verde JB, Polatti F, et al. Self-reported sexual symptoms in women attending menopause clinics. Gynecol Obstet Invest 2002;53:181–7
   PubMed Web of Science ®Google Scholar
• Nappi RE, Albani F, Santamaria V, et al. Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas 2010;67:78–83
   PubMed Web of Science ®Google Scholar
• Lachowsky M, Nappi RE. The effects of oestrogen on urogenital health. Maturitas 2009;63:149–51
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 2014;17:557–63
   PubMed Web of Science ®Google Scholar
• Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update 2012;18:405–19
   PubMed Web of Science ®Google Scholar
• Soman M, Huang L-C, Cai W-H, et al. Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis. Menopause 2019;26:78–93
   PubMed Web of Science ®Google Scholar
• Simon JA. Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil Steril 2002;77:77–82
   PubMed Web of Science ®Google Scholar
• Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001;7:535–43
   PubMed Web of Science ®Google Scholar
• Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007;22:1626–33
   PubMed Web of Science ®Google Scholar
• Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107–34
   PubMed Web of Science ®Google Scholar
• Davis SR, Worsley R, Miller KK, et al. Androgens and female sexual function and dysfunction-findings from the Fourth International Consultation of Sexual Medicine. J Sex Med 2016;13:168–78
   PubMed Web of Science ®Google Scholar
• Nappi RE, Wawra K, Schmitt S. Hypoactive sexual desire disorder in postmenopausal women. Gynecol Endocrinol 2006;22:318–23
   PubMed Web of Science ®Google Scholar
• Davis SR, Wahlin-Jacobsen S. Testosterone in women-the clinical significance. Lancet Diabetes Endocrinol 2015;3:980–92
   PubMed Web of Science ®Google Scholar
• Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause 2018;25:837–47
   PubMed Web of Science ®Google Scholar
• Traish AM, Vignozzi L, Simon JA, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev 2018;6:558–71
   PubMed Web of Science ®Google Scholar
• Nappi RE. To be or not to be in sexual desire: the androgen dilemma. Climacteric 2015;18:672–4
   PubMed Web of Science ®Google Scholar
• Aydin S, Ateş S, Arioğlu Aydin Ç, et al. The role of premature ovarian failure awareness in female sexual functions and distress. J Sex Marital Ther 2017;43:354–60
   PubMed Web of Science ®Google Scholar
• Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. J Psychosom Obstet Gynaecol 2000;21:167–74
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Luff JA, Haq NA, et al. Depression in women with spontaneous 46, XX primary ovarian insufficiency. J Clin Endocrinol Metab 2011;96:E278–87
   PubMed Web of Science ®Google Scholar
• Orshan SA, Ventura JL, Covington SN, et al. Women with spontaneous 46,XX primary ovarian insufficiency (hypergonadotropic hypogonadism) have lower perceived social support than control women. Fertil Steril 2009;92:688–93
   PubMed Web of Science ®Google Scholar
• Ventura JL, Fitzgerald OR, Koziol DE, et al. Functional well-being is positively correlated with spiritual well-being in women who have spontaneous premature ovarian failure. Fertil Steril 2007;87:584–90
   PubMed Web of Science ®Google Scholar
• Deeks AA, Gibson-Helm M, Teede H, et al. Premature menopause: a comprehensive understanding of psychosocial aspects. Climacteric 2011;14:565–72
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Cardoso GM, Ross JL, et al. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA 2006;295:1374–6
   PubMed Web of Science ®Google Scholar
• Guerrieri GM, Martinez PE, Klug SP, et al. Effects of physiological testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause 2014;21:952–61
   PubMed Web of Science ®Google Scholar
• Driscoll MA, Davis MC, Aiken LS, et al. Psychosocial vulnerability, resilience resources, and coping with infertility: a longitudinal model of adjustment to primary ovarian insufficiency. Ann Behav Med 2016;50:272–84
   PubMed Web of Science ®Google Scholar
• Rafique S, Sterling EW, Nelson LM. A new approach to primary ovarian insufficiency. Obstet Gynecol Clin North Am 2012;39:567–86
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Bitzer J, Brandenburg U, et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric 2010;13:103–20
   PubMed Web of Science ®Google Scholar
• Groff AA, Covington SN, Halverson LR, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril 2005;83:1734–41
   PubMed Web of Science ®Google Scholar
• Cooper AR, Baker VL, Sterling EW, et al. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril 2011;95:1890–97
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Premature ovarian failure: a growing concern. Climacteric 2008;11:1–3
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Premature ovarian insufficiency: working towards an international database. Climacteric 2012;15:295–6
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Iatrogenic menopause following gynecological malignancy: time for action!. Climacteric 2016;19:1–2
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Althof S, Simon JA, et al. Female sexual dysfunction-medical and psychological treatments, Committee 14. J Sex Med 2017;14:1463–91
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L, Martella S, et al. Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL). Maturitas 2016;94:87–91
   PubMed Web of Science ®Google Scholar
• Bober SL, Recklitis CJ, Bakan J, et al. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med 2015;12:189–97
   PubMed Web of Science ®Google Scholar
• Hamoda H, British Menopause Society Women’s Health Concern. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post Reprod Health 2017;23:22–35
   PubMedGoogle Scholar
• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• Committee on Gynecologic Practice. Committee opinion no. 698: hormone therapy in primary ovarian insufficiency. Obstet Gynecol 2017;129:e134–e141
   PubMed Web of Science ®Google Scholar
• Webber L, Davies M, Anderson R, et al. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016;31:926–37
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• Vujovic S, Brincat M, Erel T, et al. European Menopause and Andropause Society. EMAS position statement: Managing women with premature ovarian failure. Maturitas 2010;67:91–3
   PubMed Web of Science ®Google Scholar
• Popat VB, Vanderhoof VH, Calis KA, et al. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril 2008;89:429–33
   PubMed Web of Science ®Google Scholar
• Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014;99:3418–26
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother 2015;16:875–87
   PubMed Web of Science ®Google Scholar
• Shifren JL, Desindes S, McIlwain M, et al. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985–94
   PubMed Web of Science ®Google Scholar
• Taylor HS, Tal A, Pal L, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med 2017;177:1471–9
   PubMed Web of Science ®Google Scholar
• Davis SR, Bitzer J, Giraldi A, et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med 2013;10:3069–79
   PubMed Web of Science ®Google Scholar
• Biglia N, Maffei S, Lello S, et al. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecol Endocrinol 2010;26:804–14
   PubMed Web of Science ®Google Scholar
• Palacios S, Castelo-Branco C, Currie H, et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 2015;82:308–13
   PubMed Web of Science ®Google Scholar
• Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155–72
   PubMed Web of Science ®Google Scholar
• Fooladi E, Bell RJ, Davis SR. Management strategies in SSRI-associated sexual dysfunction in women at midlife. Climacteric 2012;15:306–16
   PubMed Web of Science ®Google Scholar
• Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause 2018;25:596–608
   PubMed Web of Science ®Google Scholar
• Achilli C, Pundir J, Ramanathan P, et al. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril 2017;107:475–82.e15
   PubMed Web of Science ®Google Scholar
• Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007;88:1–17
   PubMed Web of Science ®Google Scholar
• Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011;96:1642–53
   PubMed Web of Science ®Google Scholar
• Bell RJ, Rizvi F, Islam RM, et al. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause 2018;25:704–9
   PubMed Web of Science ®Google Scholar
• Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause 2019;26:220–4
   PubMed Web of Science ®Google Scholar
• Davis SR, Robinson PJ, Jane F, et al. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 2018;103:4146–54
   PubMed Web of Science ®Google Scholar